{"organizations": [], "uuid": "aae9e1d72283868119acce10c4c5fdd409deb4eb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lilly-and-sigilon-therapeutics-ann/brief-lilly-and-sigilon-therapeutics-announce-strategic-collaboration-to-develop-encapsulated-cell-therapies-idUSFWN1RH04N", "country": "US", "domain_rank": 408, "title": "BRIEF-Lilly And Sigilon Therapeutics Announce Strategic Collaboration To Develop Encapsulated Cell Therapies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-04T14:11:00.000+03:00", "replies_count": 0, "uuid": "aae9e1d72283868119acce10c4c5fdd409deb4eb"}, "author": "", "url": "https://www.reuters.com/article/brief-lilly-and-sigilon-therapeutics-ann/brief-lilly-and-sigilon-therapeutics-announce-strategic-collaboration-to-develop-encapsulated-cell-therapies-idUSFWN1RH04N", "ord_in_thread": 0, "title": "BRIEF-Lilly And Sigilon Therapeutics Announce Strategic Collaboration To Develop Encapsulated Cell Therapies", "locations": [], "entities": {"persons": [{"name": "sigilon", "sentiment": "none"}, {"name": "lilly", "sentiment": "none"}], "locations": [], "organizations": [{"name": "eli lilly and co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "develop encapsulated cell therapies reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4, 2018 / 11:12 AM / in 13 minutes BRIEF-Lilly And Sigilon Therapeutics Announce Strategic Collaboration To Develop Encapsulated Cell Therapies Reuters Staff 2 Min Read \nApril 4 (Reuters) - Eli Lilly and Co: \n* LILLY AND SIGILON THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP ENCAPSULATED CELL THERAPIES FOR THE TREATMENT OF TYPE 1 DIABETES \n* SIGILON TO RECEIVE UPFRONT PAYMENT OF $63 MILLION AND UNDISCLOSED EQUITY INVESTMENT \n* PRODUCING CELLS FOR POTENTIAL TREATMENT OF TYPE 1 DIABETES \n* LILLY WILL RECEIVE AN EXCLUSIVE WORLDWIDE LICENSE TO SIGILON’S AFIBROMER TECHNOLOGY FOR ISLET CELL ENCAPSULATION \n* SIGILON IS ALSO ELIGIBLE TO RECEIVE UP TO $410 MILLION IN DEVELOPMENT AND COMMERCIALIZATION MILESTONES \n* PROCESS RESEARCH AND DEVELOPMENT CHARGE TO EARNINGS OF APPROXIMATELY $0.05 PER SHARE IN Q2 OF 2018 \n* ‍AFTER IND IS SUBMITTED,CO WILL BE RESPONSIBLE FOR ALL CLINICAL DEVELOPMENT & COMMERCIALIZATION ACTIVITIES & COSTS RELATED TO COLLABORATION​ \n* GAAP EARNINGS PER SHARE GUIDANCE AS A RESULT OF THE TRANSACTION \n* ‍SIGILON WILL BE RESPONSIBLE FOR ALL DEVELOPMENT ACTIVITIES & COSTS RELATED TO COLLABORATION UNTIL SUBMISSION OF IND \n* SIGILON ELIGIBLE TO GET SINGLE TO DOUBLE DIGIT TIERED ROYALTIES ON FUTURE PRODUCT SALES IF DEAL YIELDS COMMERCIALLY SUCCESSFUL PRODUCT Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-04-04T14:11:00.000+03:00", "crawled": "2018-04-04T14:28:03.023+03:00", "highlightTitle": ""}